News
Video
Author(s):
Benjamin Solomon, MBBS, PhD, FRACP, presents key data from the ALINA study investigating alectinib versus chemotherapy as adjuvant therapy in patients with stage IB–IIIA anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC).